Aflibercept

Other Ophthalmologicals · Vascular endothelial growth factor inhibitor

Indications

Neovascular (wet) age-related macular degeneration (AMD). Visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).

Dosage

Adults: AMD: 2 mg by intravitreal injection every mth for 3 mth, then every 2 mth. Review treatment interval after 12 mth based on visual and anatomic outcomes. CRVO: 2 mg by intravitreal injection every mth until visual and anatomic outcomes are stable. If necessary, continue with gradually increasing treatment intervals to maintain outcomes. Monitor after discontinuation and resume if deterioration. Discontinue if no improvement within first 3 mth. Children: Not recommended.

Adverse Effects

Conjunctival and intraocular haemorrhage, eye pain and irritation, anterior chamber flare, increased IOP, blurred vision, increased lacrimation, eyelid oedema, vitritis, uveitis, iritis, vitreous floaters, vitreous detachment, retinal detachment and degeneration, cataract corneal abrasion and oedema, ocular hyperaemia. Advise patient to report of non-ocular haemorrhage and arterial thromboembolic events.

Risk Factor (Pregnancy/Lactation)

Contraindications: Lactation. Ocular or periocular infection, severe intraocular inflammation. Signs of irreversible ischaemic visual function loss. Precautions: Pregnancy; ensure contraception in women and continue for 3 months after treatment. Elevation in IOP may occur; monitor perfusion of the optic nerve head and IOP. Advise patients to report symptoms of intraocular inflammation without delay. Risk factor for retinal pigment epithelial tears. Withhold in event of decreased in best-corrected visual acuity = 30 letter, IOP =30mmHg, retinal tear, intraocular surgery within 28 days, or subretinal haemorrhage = 50% of total lesion size or involving centre of fovea. Diabetic retinopathy.

Interactions

Verteporfin.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.